drugset / Trial / NCT04970108
Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Egito association in the treatment of type 2 diabetes mellitus and hypertension
Timeline
- Start
- 2023-08
- Primary completion
- 2025-01
- Completion
- 2025-05
Outcome
Outcome not reported
Stopped (Business): “Strategy review”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Egito | Unknown | — | Oral |
| Comparator | Empagliflozin | Small molecule | 25 mg | Oral |
| Comparator | Telmisartan | Other / unclassified | 40 mg | Oral |
| Comparator | Telmisartan | Other / unclassified | 80 mg | Oral |